Press Release: ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP
ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3…
Anthos Therapeutics Shares New Analysis from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Substantially Reduced Bleeding in Patients on Antiplatelet Therapy Compared to Rivaroxaban
November 16, 2024 16:38 ET | Source: Anthos Therapeutics Data presented at…